Daniel Hunt

Bio:

Dan joined Allogene shortly after its founding in 2018 and has since led multiple strategic and technology transactions to support the company’s core mission to bring the promise of allogeneic CAR T therapy to patients. Prior to Allogene, he filled a similar role at Fluidigm Corporation, a pioneer in single cell genomics and high-parameter proteomic technologies, where he led multiple initiatives including spearheading the company’s multi-product immunotherapy strategy. The first half of Dan’s 25-year career in the health technology industry was spent as an investment professional, first at SG Cowen & Co (now TD Cowen), and then spending nearly a decade as a portfolio manager and analyst at Allianz Global Investors (RCM) in San Francisco. He holds a B.A. from Stanford University and an MSc from the London School of Economics and Political Science.